Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Ahmed, Mahiuddin ^a   Hu, Jian ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody engineering; Computational chemistry; Ganglioside; Melanoma; Neuroblastoma; Structure

Indexed keywords

EID: 84923091515     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00372     Document Type: Article

References (21)

1. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett (2014) 588(2):288-97. doi: 10.1016/j.febslet.2013.11.030
2. Lammie GA, Cheung NKV, Gerald W, Rosenblum M, Cordon-Cardo C. Ganglioside GD2 expression in the human nervous system and in neuroblastomas - an immunohistochemical study. Int J Oncol (1993) 3:909-15.
3. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 45(6):2642-9.
4. Chang HR, Cordon-Cardo C, Houghton AN, Cheung NK, Brennan MF. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 70(3):633-8. doi:10.1002/1097-0142(19920801)70:3<633::AID-CNCR2820700315>3.0.CO;2-F
5. Grant SC, Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, et al. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med (1996) 23(2):145-9. doi:10.1007/BF01731837
6. Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori SI. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A (2013) 110(13):4968-73. doi:10.1073/pnas.1302825110
7. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 122(6):2066-78. doi:10.1172/JCI59735
8. Yanagisawa M, Yoshimura S, Yu RK. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro (2011) 3(2): doi:10.1042/AN20110006
9. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood (2007) 109(10):4245-8. doi:10.1182/blood-2006-08-039347
10. Jin HJ, Nam HY, Bae YK, Kim SY, Im IR, Oh W, et al. GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. Cell Mol Life Sci (2010) 67(11):1845-58. doi:10.1007/s00018-010-0292-z
11. Saito M, Yu RK, Cheung NKV. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun (1985) 127(1):1-7. doi:10.1016/S0006-291X(85)80117-0
12. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol (1987) 5(9):1430-40.
13. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. OncoImmunology (2012) 1(4):477-86. doi:10.4161/onci.19864
14. Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 30(26):3264-70. doi:10.1200/JCO.2011.41.3807
15. Ahmed M, Goldgur Y, Hu J, Guo HF, Cheung NK. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS One (2013) 8(5):e63359. doi:10.1371/journal.pone.0063359
16. Gao SH, Huang K, Tu H, Adler AS. Monoclonal antibody humanness score and its applications. BMC Biotechnol (2013) 13(55): doi:10.1186/1472-6750-13-55
17. Hakomori S. Role of gangliosides in tumor progression. In: Svennerholm L, Asbury AK, Reisfeld RA, Sandhoff K, Suzuki K, Tettamanti G, editors. Progress in Brain Research. Netherlands: Elsevier Science BV (1994).
18. Kuroda D, Shirai H, Jacobson MP, Nakamura H. Computer-aided anti- body design. Protein Eng Des Sel (2012) 25(10):507-21. doi:10.1093/protein/gzs024
19. Wang T, Duan Y. Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study. Protein Eng Des Sel (2011) 24(9):649-57. doi:10.1093/protein/gzr029
20. Cheng M, Ahmed M, Xu H, Cheung N-KV. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer (2014): doi:10.1002/ijc.29007
21. Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, et al. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Eng Des Sel (2012) 25(1):1-6. doi:10.1093/protein/gzr053